Objective: To evaluate the efficacy and drug resistance of azithromycin administered via continuous infusion versus intermittent administration in rats with Mycoplasma pneumonia-induced pneumonia.
Methods: Pneumonia was induced in rats by intranasal administration of mycoplasma suspension. The rats with established pneumonia were randomly divided into continuous and intermittent infusion groups with intraperitoneal azithromycin injection on a daily basis for 6 consecutive days, or for 3 consecutive days followed by a 3-day rest (which was repeated twice), respectively. The bronchoalveolar lavage (BAL) and venous blood were collected before and at 3, 6, 9, and 12 days during or after the treatments for MIC test. The rats were killed for lung pathological examination, and the plasma samples were obtained for drug assays by HPLC.
Results: Pathological examination of the lungs demonstrated better improvement in the intermittent group than in continuous group. At 12 days of the treatment, the MIC value was higher in the continuous group than in the intermittent group.
Conclusion: Intermittent azithromycin administration produces better therapeutic effect against Mycoplasma pneumonia than continuous drug delivery in rats with less likeliness of inducing drug resistance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.
Discov Nano
January 2025
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome. Conventional liposomes have been explored as a delivery system for infectious diseases bioactives to treat infectious diseases to provide an efficient approach to maximize the therapeutic outcomes, drug stability, targetability, to reduce the side-effects of antimicrobials, and enhance vaccine performance where necessary.
View Article and Find Full Text PDFTargeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds.
Mol Biol Rep
January 2025
Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system.
View Article and Find Full Text PDFRole of glycosylation in bacterial resistance to carbapenems.
World J Microbiol Biotechnol
January 2025
School of Medicine, Faculty of Life Science & Medicine, Northwest University, Xi'an, China.
Carbapenems are a class of β-lactam antibacterial drugs with a broad antibacterial spectrum and strong activity, commonly used to treat serious bacterial infections. However, improper or excessive use of carbapenems can lead to increased bacterial resistance, which is a significant concern as they are often used as last resort for treating multidrug-resistant (MDR) gram-negative bacteria. Confronted with this challenge, it is crucial to comprehensively understand the mechanism of carbapenem resistance to develop effective therapeutic strategies and innovative drugs.
View Article and Find Full Text PDFCorrection: HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway.
Discov Oncol
January 2025
Department of Colorectal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou, 325000, Zhejiang, China.
Alpelisib is a phosphatidylinositol 3-kinase inhibitor approved by the US Food and Drug Administration for the treatment of hormone receptor-positive metastatic breast cancer with (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) mutation. In recent years a number of adverse effects have been observed to be associated with this therapy, the most notable of which is hyperglycemia. A literature search was conducted to include case studies, case series, systematic reviews, and meta-analyses within the last 10 years that evaluated patients with mutated hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!